ESR1 and breast carcinoma: Patients with TNBC have poorer prognosis and higher risk of recurrence than patients with ER(+) or HER2/neu-(+) breast cancer; TNBC is a clinically aggressive disease associated with distant recurrence and high rates of visceral and central nervous metastases [3, 4].